Alzamend Neuro, Inc. · NASDAQ:ALZN
Alzamend Neuro — Investor Presentation (August 2022)
27 slides from Alzamend Neuro's investor presentation, Aug 15, 2022
Slide 1: Alzamend Neuro, Inc. Corporate Presentation August 2022
Alzamend Neuro, Inc. Corporate Presentation August 2022
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the “Company” or “ Alzamend ”) contain “forward looking statements” within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Se
Slide 3: Table of Contents
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. TABLE OF CONTENTS 3 Introduction Company Overview 4 - 8 Overview of Alzheimer’s Disease Alzheimer’s Disease 9 Economic Burden 10 Therapeutic Landscape 11 Our Science General Scientific Overview 12 AL0
Slide 4: Company Overview
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION NASDAQ: ALZN 4 Industry Biopharmaceutical Sector Small Molecule / Cell Therapy Founded 2016 IPO June 15, 2021 Last Reported Cash $14.1 Million (Per our 10 - K filed on Ju
Slide 5: Lead Drug Candidate – Ionic Cocrystal of Lithium (AL001)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Lead Drug Candidate – Ionic Cocrystal of Lithium (AL001) 5 Multiple Indications Bioequivalent to Marketed Lithium Therapies Market Opportunity » AL001 is a patented ionic
Slide 6: Reference to AL001: Current Marketed Lithium – Lithium Carbonate
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Reference to AL001: Current Marketed Lithium – Lithium Carbonate 6 Usage For BD , MDD, PTSD Challenges Published Clinical Efficacy Studies For Alzheimer’s » Approved by t
Slide 7: Product Candidate Pipeline
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. 7 Product Candidate Indication Pre - Clinical Phase I Phase II Phase III FDA Approval AL001 • Alzheimer’s Disease • Bipolar Disorder • Major Depressive Disorder • Post - Traumatic Stress Disorder AL00
Slide 8: Company History and Current Pipeline
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Company History Current Pipeline 8 AL001 (aka LISPRO): • an ionic cocrystal (“ICC”) of lithium for the potential treatment of Alzheimer’s Disease, BD, MDD and PTSD. AL002
Slide 9: Alzheimer's Disease
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzheimer’s Disease OVERVIEW OF ALZHEIMER’S DISEASE 9 Alzheimer’s Disease: Alzheimer’s Disease is an irreversible, progressive brain disorder that slowly destroys memory and cognitive skills , and eve
Slide 10: Economic Burden
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Important Implications Economic Burden 1. In 2022, the estimated healthcare costs for treating individuals with Alzheimer’s Disease in the United States will be $321 billion , including $206 billion i
Slide 11: Therapeutic Landscape
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Therapeutic Landscape 11 OVERVIEW OF ALZHEIMER’S DISEASE https://alz - journals.onlinelibrary.wiley.com/pb - assets/DADM/TRCI%20Drug%20Pipeline%20Infographic - DoctorAudience - 2021%20 - %20No%20 AA%2
Slide 12: Overview of Our Science
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Our Science GENERAL SCIENTIFIC OVERVIEW 12 Therapeutic Drug Synopsis Strength Status AL001 ▪ Use of patented ICC technology delivering a therapeutic combination of Lithium, Proline, and Sa
Slide 13: AL001 Phase IIA Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 Phase IIA Trial 13 Study No. Study Title Description Status AL001 - ALZ02 (US) A Multiple - dose, Steady - state, Double - blind, Ascending Dose Safety, Tolerability, Pharmacokinetic Study of AL
Slide 14: AL001 Phase I Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 Phase I Trial 14 Study No. Study Title Description Status AL001 - ALZ01 (US) A randomized, balanced, Phase I, single - dose, open - label, two - treatment, two - period, two sequence, crossover,
Slide 15: Select Results from Phase I Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Safety/Tolerability: Primary Endpoint Met Select Results from Phase I Trial 15 » AL001 was shown to be safe and well - tolerated in healthy adult subjects » No serious adverse events and no deaths wer
Slide 16: AL001 (aka LISPRO)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO ) 16 • AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium , proline and salicylate • AL001 exhibits improved non - clinical pharmacokineti
Slide 17: AL001 (aka LISPRO) Preclinical Results
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO) 17 The results of our preclinical studies, conducted from May 2016 to June 2017 , are summarized below : • AL 001 had no effect on renal COX 2 activity ( Tg - Ctrl vs . AL 001 : p >
Slide 18: AL001 (aka LISPRO) Preclinical Studies
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO) 18 • Our pre - clinical studies encompassed the treatment of 28 transgenic (or genetically modified) and 10 non - transgenic mice with lithium carbonate and AL001. • Female APPSWE/P
Slide 19: Overview of AL002 (aka E22W)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of AL002 (aka E22W) 19 • Our goal is to develop an Alzheimer’s Abeta vaccine candidate that will be devoid of the problems associated with current vaccine therapies. Our studies concluded the
Slide 20: Overview of AL002 (aka E22W)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of AL002 (aka E22W) 20 • We illustrated our result by using Abeta peptide pulsed Dendritic Cells (“DC”) as a vaccine in Tg APP/PS1 mice. • ABeta 1 - 42 with different mutation were synthesize
Slide 21: Overview of Alzamend Neuro's Intellectual Property
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Alzamend Neuro’s Intellectual Property (Licensed Patents) ALZAMEND NEURO 21 Title of Patent Patent Type Therapeutic Drug Date Filed Date Issued Expiration Date Patent # Lithium Cocrystals
Slide 22: Overview of Alzheimer's Disease Drugs on the Market
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Alzheimer’s Disease Drugs on the Market COMPETITIVE LANDSCAPE 22 Aricept Exelon Namenda Razadyne *Aricept – Eisai Co., Ltd., Financial Results for Fiscal 2020(3/31/2021 for JPY FX) ( https
Slide 23: Overview of Market Opportunity for AL001 and AL002
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Market Opportunity for AL001 and AL002 COMPETITIVE LANDSCAPE 23 Patient Population United States Global (Including US) MDD 21 Million¹ 280 Million² PTSD 9 Million¹ 284 Million² Alzheimer ’
Slide 24: Alzamend Leadership Team
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Leadership Team ALZAMEND NEURO 24 Stephan Jackman Chief Executive Officer and Director 20+ years multi - industry experience, specialized in Biotech and Pharmaceutical Kenneth S. Cragun Senio
Slide 25: Alzamend Scientific Advisory Board
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Scientific Advisory Board ALZAMEND NEURO 25 Thomas M. Wisniewski, MD Director, NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment 300+ Peer - Reviewed Medical Journal Pu
Slide 26: Advisors and Board of Directors
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Lynne Fahey McGrath, Ph.D. Regulatory Affairs and Product Development Consultant 30+ years experience, Biotech and Pharmaceuticals M.P.H./Ph.D., Public Health from UMDNJ – Robert Wood Johnson Medical
Slide 27: Contact Us
CONTACT US 3500 Lenox Road, Suite 1500 Atlanta, GA 30326 +1 (844) 722 - 6333 Info@alzamend.com www.alzamend.com